PT  - JOURNAL ARTICLE
AU  - Zhang, Liangsheng
AU  - Yang, Jian-Rong
AU  - Zhang, Zhenguo
AU  - Lin, Zhenguo
TI  - Genomic variations of COVID-19 suggest multiple outbreak sources of transmission
AID  - 10.1101/2020.02.25.20027953
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.25.20027953
4099  - http://medrxiv.org/content/early/2020/02/26/2020.02.25.20027953.short
4100  - http://medrxiv.org/content/early/2020/02/26/2020.02.25.20027953.full
AB  - The most important finding of this study is that COVID-19 strains form two well-supported clades (genotype I, or Type I, and Type II). Type II strains were likely evolved from Type I and are more prevalent than Type I among infected patients (68 Type II strains vs 29 Type I strains in total). Our results suggest the outbreak of type II COVID-19 likely occurred in the Huanan market, while the initial transmission of the type I virus to humans probably occurred at a different location in Wuhan. Second, by analyzing the three genomic sites distinguishing Type I and Type II strains, we found that the synonymous changes at two of the three sites confer higher protein translational efficiencies in Type II strains than in Type I strains, which might explain why Type II straints are more prevalent, implying that Type II is more contagious (transmissible) than Type I. These findings could be valuable for the current epidemic prevention and control. The timely sharing of our findings would benefit the public health officials in making policies, diagnosis and treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere are no fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe obtained 97 complete genomes of COVID-19 samples from GISAID (www.gisaid.org), NCBI and NMDC (http://nmdc.cn/#/nCov/).